metabolite

[키워드] 1:1 24 hours Ability absence addition adhere Affect age Ageusia allergy analysed Anosmia Anosmia/ageusia Antacid Antibiotics Antiviral assessment assigned Autoimmune disease Bariatric surgery baseline bilevel positive airway pressure Biomarker Biomarkers biomarkers of inflammation BiPAP Blinding blocker Blood blood sample Blood samples both groups bowel bowel resection breath Care care provider Cell change Chest chest tightness chills chronic lung disease cirrhosis clinical clinical study clinical trial Cold collected Community Comorbidity comparator Patients completion Compliance component computer Concomitant medication concomitant medications concurrent condition conducted contraindications coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 in patient COVID-19 symptom COVID-19 symptoms COVID-19 testing COVID-19-related symptom COVID-19-related symptoms COVID-19–related symptom COVID-19–related symptoms CPAP Cytokines D-dimer daily dose Day defined diarrhea dissemination drug duration of symptom Effect element eligible Enrollment evaluate evaluate the effect evaluated exacerbated exclusion criteria exploratory fatigue fatty Fatty acid feasible Female patients Fever fiber Follow-up follow-up period following group Gut gut microbiome gut microbiome composition gut microbiota headache Health Health care Health Care Utilization Health status healthcare Histamine history hospital Hospital admission Hospital admissions Hospitalization Hospitalized hypoxia Identifier IgM/IgG Immunity immunomodulatory immunosuppressive immunosuppressive therapy in both group include Infection Inflammation Inflammatory biomarker Inflammatory bowel disease information Informed consent inhibitors intake Interaction investigational agent irritable bowel syndrome KB109 Laboratory laboratory measures lactating library life Liver disease Lung disease magnitude malignancy management measure Measures medication medications Medicine metabolite Microbiome microbiota Mild mild to moderate Mild to moderate COVID-19 mild to moderate disease moderate Moderate COVID-19 moderate disease modulate modulation muscle pain nasal congestion neutralization assays not limited nucleic acid number objective Open-label opinion other compound other compounds outcome outcome measure Outpatient outpatients oxygen oxygen saturation Oxygen therapy Pain parallel group participant Participation Patient patient population Period Physical examination positive airway pressure Positive test Potential pre-symptomatic pregnant Primary outcome progression proportion proportions Prospective Study PROTECT protocol protocols proton pump provided pulse Pulse oximeter Quality of life Quantitative question randomisation randomised randomised controlled study randomization Randomized randomized controlled study receive recruitment reduction Registered reported response resting position risk risk of infection Sample size screened selected self-care sensitivities Sequencing serological serology shaking short-chain fatty acids Shortness of breath Sleep sleep apnea Smartphone sore throat specific biomarker specific biomarkers Spread SSC Standard Stool stratified Study design Study protocol study visit supplementary material Swab Symptom symptomatic patient Symptomatic patients Symptoms syndrome Tablet TEAEs Telemedicine telephone temperature the patient The United States therapy time Tolerability Treatment treatment-emergent adverse event undergo United States unlikely Viral Viral load water website worsening
[DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter